Feedback / Questions
sonelokimab (M1095) - Avillion, MoonLake Immunotherap
https://www.globenewswire.com/news-release/2026/06/21/3314997/0/en/moonlake-announces-week-52-results-of-sonelokimab-from-its-phase-3-vela-program-in-hidradenitis-suppurativa-and-confirms-investor-day-on-june-22-2026.html
Jun 21, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next